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Abstract: Gluten-related disorders have recently been reclassified with an emerging scientific
literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has
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specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E
(non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms.
This review article will provide clinicians with an update that directly impacts on the management of
a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion.
Keywords: gluten sensitivity; celiac disease; wheat allergy; gluten-related disorders; gluten-free diet;
amylase-trypsin inhibitors (ATIs)
1. Introduction
Non-celiac gluten sensitivity (NCGS), sometimes referred as gluten sensitivity, gluten intolerance,
or non-celiac wheat sensitivity, was already described in 1978 but did not receive much recognition
from clinicians until the 21st century [1]. It is characterized by intestinal and extra-intestinal symptoms
related to the ingestion of gluten-containing food, in subjects that are not affected by either celiac
disease (CD) or wheat allergy (WA). This is the original definition based on the Salerno Experts’
Criteria [2]. However, our understanding has evolved since that time and we recognized that the
spectrum of symptoms, which occur maybe due not just to the ingestion of gluten proteins but
potentially other wheat-related components. In clinical practice, it is crucial to exclude CD in patients
who present in this way. A recent PubMed search using the Medical Subject Headings (MeSH) index
term of NCGS demonstrates 125 publications prior to 2000 but 490 since the start of the new millennium.
Public and commercial interest in a gluten free diet (GFD) has galvanized the scientific community
into undertaking research beyond the previously recognized gluten-related disorders such as celiac
disease or dermatitis herpetiformis.
Irritable bowel syndrome (IBS) is a common intestinal disorder causing abdominal pain, bloating,
gas, diarrhea and constipation. IBS-like complaints are often part of the NCGS clinical picture.
Conversely, recent studies support the hypothesis that gluten and other wheat components may
trigger IBS symptoms. Due to this overlap and lack of IBS/NCGS biomarkers, and there is a confusing
situation for both the primary care physician and the general audience. This review article is aimed to
present (1) an update on the complex relationship between NCGS and IBS and (2) the experts’ opinion
on this hot topic.
2. Methods
In order to provide consensus and promote collaborative research in this field, a group of
23 experts convened in Meran, Italy in December 2016. Each expert was assigned to separate work
streams according to their areas of clinical and research experience. Work streams involved review
of recent literature using PubMed and Embase Databases. The previous literature review occurred
at the Salerno meeting in October 2014. For this reason, the new MeSH-based literature review
encompassed all articles since that time but also key historical papers. Furthermore, experts in
attendance were also asked to identify emerging studies (presented in abstract form). The experts were
then divided into work streams, with sub-section presentations and break-out focus groups. Based on
this current evidence, five areas were identified where significant progress within the medical literature
has occurred: (1) Prevalence studies of NCGS; (2) Non-IgE wheat allergy; (3) Potentially harmful
wheat components; (4) Pathogenetic mechanisms for IBS triggered by wheat; (5) Overlap between
IBS-type symptoms and NCGS. This review provides the summary and consensus (undertaken using
a Delphi method) from this International Workshop.
2.1. Prevalence of NCGS: Emerging Data and Ascertainment Pitfalls
We have previously categorized the spectrum of gluten-related disorders and provided
a “road map” for clinicians seeking to manage their patients who have gluten-related symptoms [2–4].
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Considering the uncertainty regarding the prevalence of NCGS, initial efforts at the Center for Celiac
Research, University of Maryland (USA) were aimed at clarifying this with an original report of their
experience with 5896 patients seen between 2004 and 2010 [3]. The criteria for NCGS were fulfilled
by 347 patients suggesting a prevalence in their study population of 6% (1:17). The limitation to this
important observation is that this is a tertiary center seeing patients within a fee-paying system. Due to
a selection bias, this may not accurately reflect international prevalence figures for NCGS.
Since that time other international groups have tried to estimate the prevalence of NCGS
(Table 1) [5–14]. Of these studies, three report data from the National Health and Nutrition Examination
Survey (2009–2010), with the most recent study incorporating data from 2011 to 2012 [6,7,12]. The range
when considering the general population and ensuring exclusion of CD, highlights a prevalence
between 0.6% and 10.6%. The huge variability in prevalence figures is mainly explained by lack of
diagnostic biomarker(s). In order to clarify the diagnosis of NCGS, at a previous consensus meeting
the experts’ group recommended a double-blind placebo controlled (DBPC) approach using 8 grams of
gluten [4]. Although a DBPC approach is the gold standard for a rigorous scientific identification of true
cases, this is difficult to undertake in daily clinical practice. Patients frequently refuse to re-introduce
gluten into their diet due to the immediate symptom burden which they perceive. This view is further
reflected by the high levels of unsuccessful patient recruitment in studies to resolve these specific issues
reported in the literature. There is still very limited data on the overlap between NCGS and IBS-type
symptoms. The UK population survey undertaken in 1002 adults demonstrated that individuals with
NCGS had an increased prevalence of fulfilling the Rome III criteria for irritable bowel syndrome in
comparison with those without NCGS (20% vs. 3.89%, odds ratio 6.23, p < 0.0001) [8].
Table 1. Prevalence studies of people avoiding gluten-based products.
Author Year ofPublication Country Group Sample Size
Avoidance of
Gluten-Based
Products
Known Previous
Diagnosis of CD
Tanpowpong
et al. [5] 2012 New Zealand Children-general population 916 5% (n = 48) 1% (n = 9)
Rubio-Tapia
et al. [6] 2013 USA
Age ≥ 6 years, National Health and
Nutrition Examination Survey
(NHANES) 2009–2010
7798 0.63% (n = 55) 0.1% (n = 6)
DiGiacomo
et al. [7] 2013 USA NHANES 7762 0.6%
Aziz et al.
[8] 2014 UK Adults-general population 1002 3.7% (n = 37) 0.8% (n = 8)
Lis et al. [9] 2014 Australia Adults-athletes 910 41.2% (n = 375) None
Volta et al.
[10] 2014 Italy
Adult and pediatric GI
clinic population 12,225 391 (3.2%)
Within same
population 340 (2.8%)
coeliac patients
diagnosed
Golley et al.
[11] 2015 Australia Adults-general population 1184 10.6% (n = 126) 1.2% (n = 14)
Mardini et al.
[12] 2015 USA
Age ≥ 6 years, NHANES
2009–2010 & 2011–2012
data combined
14,701 0.9% (n = 142) 0.1% (n = 21)
Van Gils T
et al. [13] 2016
The
Netherlands Adults-general population 785 6.2% (49/785) 0.25% (2/785)
Carroccio A
et al. [14] 2017 Italy Age 14–18 548 2.9% (16/548) 1.26% (7/555)
An emerging epidemiological issue is represented by self-reported NCGS, i.e., people excluding
gluten-containing food without a medical diagnosis of a specific gluten-related disorder.
Many individuals perceive the GFD as healthy life style practice. This group may be termed lifestyles,
free from or clean eaters depending on which country they reside in. We propose to define them
as people who avoid gluten [5–14]. These individuals are widely diffused in Western countries,
with a prevalence of 6.2–13% [8,13].
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They must be treated with great caution and if such patients present to clinicians it is imperative
to first exclude celiac disease [2–4] or other causes not related to any specific trigger (placebo effect,
implementation of a healthier diet, etc.). Such patients can be advised that simply by identifying gluten
as a culprit for their symptoms, this gives them a risk ranging from 2% to 42% of having undiagnosed
celiac disease (based on the current published literature) [8,15–19]. This extreme variation reflects
an ascertainment bias related to the referral patterns of the centers that have published their data.
Tertiary and quaternary centers may have a high prevalence of patients presenting with gluten-related
symptoms who are subsequently recognized to have celiac disease.
2.2. Update on Non-IgE Mediated Wheat Allergy in NCGS
Wheat allergy is an adverse immune response which occurs reproducibly in affected individuals.
The immune mechanism may be IgE or non-IgE mediated. Individuals may have a serological
IgE response to wheat but this only demonstrates sensitization. To make a diagnosis of wheat
allergy, patients must also describe reproducible symptoms and signs which occur quickly following
wheat exposure. Typically, these symptoms may be gastrointestinal, respiratory, at skin level
and in some rare cases anaphylaxis or angioedema [20,21]. Recent developments have occurred
specifically in the field of adult non-IgE-mediated food allergy. Non-IgE-mediated food allergy is
a condition well known by pediatricians who recognize at least three gastrointestinal clinical conditions:
the food protein-induced enterocolitis syndrome, the food protein-induced proctocolitis, and the food
protein-induced enteropathies [20]. In the pediatric population, this condition is mainly due to cow’s
milk protein hypersensitivity (CMPH) but also soya (most common triggers). Wheat is also involved
in Food Protein Induced Enteropathy in children. It is difficult to diagnose as radioallergosorbent test
or skin testing are neither specific nor sensitive. For this reason, a CMPH diagnosis must be posed
exclusively on clinical basis by means of elimination diet and successive DBPC food challenge [22].
It is probable that in adults, the allergy-related gastro-intestinal symptoms are common and often
underestimated [21] (confocal/ review recent papers).
The hypothesis that NCGS could be a non-IgE-mediated wheat allergy is based on some clinical
aspects (presence of a personal history of food allergy in the pediatric age, or of coexistent atopic
diseases) [22], laboratory and histological data (positive serum anti-gliadin antibodies, positive
cytofluorimetric assay revealing in vitro basophil activation by food antigens, and presence of
eosinophils in the intestinal mucosa biopsies) [23–25] and by new and exciting endoscopic findings
(see below) [26]. Further studies are required to explore the putative allergic mechanisms involved
in the pathogenesis of NCGS. Recently immunological activation in the intestinal mucosa of the
NCGS patients has been demonstrated. In fact, gastrointestinal food allergies are often mediated
by IgE-independent mechanisms involving mast cells, eosinophils, and other immune cells [21].
An increase in mucosal lymphocytes has been reported in a consistent percentage of patients with
NCGS diagnosed by DBPC challenge [25,27], and in general most of the studies on NCGS showed that
about half of the patients have a raised IELs count >25 per 100 enterocytes [23,28,29]. Very recently,
an increased infiltration of innate lymphocytes-1 cells, producing IFN-γ, in the rectal mucosa of NCGS
patients has been reported; furthermore, this infiltration decreased after resuming a wheat-free diet [30].
Given these conflicting observations further work is required to clarify whether NCGS could have
an association with either IgE or non IgE mediated wheat allergy.
There is a lack of consensus about intestinal permeability in NCGS. After a first report suggesting
a reduced intestinal permeability [28], more recent studies have demonstrated an increased permeability
in NCGS [31,32]. Uhde et al., in particular, were able to demonstrate a state of systemic immune
activation, partly in response to translocated microbial components and possibly in conjunction
with a compromised intestinal epithelium, which significantly improved on a wheat-free diet.
Further studies are needed to decipher how wheat components can contribute to a compromised gut
epithelial barrier and subsequent microbial translocation that result in systemic immune activation.
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In this respect, the exciting findings by confocal endomicroscopy could be the keystone. Recently
a novel strategy to identify IBS patients with food-related symptoms and specified sensitivities has
been described [26]. Within five minutes after the administration of defined food suspensions to the
duodenal mucosa of sensitive patients, confocal laser endomicroscopy demonstrated an increase in
the number of intraepithelial lymphocytes, epithelial shedding and breaks followed by leaks with
secretion of fluorescein into the lumen, and edema with increased inter-villous spaces. Characteristic
mucosal changes after administration of a wheat suspension were seen in 13 (and after administration
of milk, soy and yeast in another 9) of 36 IBS patients, and in all of the dietary elimination of the
identified trigger, including wheat as prominent cause, resulted in a long-term improvement of
symptoms. The 36% of wheat-sensitive IBS patients is in line with the proportions revealed in other
studies [21,22], and suggests that this method may offer a remarkable sensitivity and specificity for
NCGS. A German multi-center study (DRKS00010123) is currently recruiting patients to further validate
these findings [33]. Finally, it is worth noting that endomicroscopy with several food challenges is
a complex investigation requiring the patient’s sedation.
2.3. Potentially Harmful Wheat Components
Several components of wheat are potentially harmful for NCGS and IBS patients including
gluten proteins, lipopolysaccharides, amylase/trypsin inhibitors (ATIs), wheat germ agglutinins
(WGA) and fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) (Figure 1) [32,34–37].
Gluten proteins, the storage proteins of wheat, rye and barley, account for 70–80% of the total grain protein
and are located exclusively in the starchy endosperm of the grains (Figure 2). The remaining proteins
are albumins and globulins (20–30%) that have metabolic, protective or structural functions. Largely
insoluble in water and salt solution, gluten can be subdivided into mostly monomeric prolamins
(called gliadins in wheat) soluble in aqueous alcohols and polymeric glutelins (called glutenins in
wheat) soluble only in the presence of reducing and disaggregating agents [38]. Specific sequences
from gluten, e.g., N-terminal peptides from α-gliadin, have been shown to induce an innate immune
response in celiac disease [39,40] and could also play a role in NCGS. In general, care is advised when
using wheat or gluten for oral challenge, because all wheat is not the same and all gluten is not the same.
The composition of the individual components and the overall protein contents can differ in a rather
large range depending on wheat species, cultivar, growing conditions (e.g., soil, climate, fertilization)
and processing, in the case of gluten and, especially, hydrolyzed gluten. Therefore, each material
should be well characterized using proteomic methods and, if possible, standardized [41].
ATIs are a family of at least 11 structurally similar, small and compact mono-, di- or tetrameric
wheat proteins, which serve as protective proteins in wheat and other cereals by inhibiting enzymes
(amylase and trypsin-like activities) of wheat and some parasites. In the developing grain, ATIs are
deposited together with gluten proteins in the endosperm and become associated with the starch
granules [42]. Encoded mainly by the B and D genomes, ATIs are high in most modern hexaploid bread
wheats, and low in spelt (old hexaploid), tetraploid (durum wheat, emmer) and diploid (einkorn) wheat
species. They are also present in other gluten containing cereals such as barley and rye. Long known
as major allergens in baker’s asthma [43], ATIs were identified as triggers of innate immune activation
in intestinal myeloid cells via stimulation of Toll-like receptor 4 (TLR4) [35]. Notably, nutritional
ATIs enhance intestinal inflammation in models of inflammatory bowel disease in mice, and immune
activation is higher in the mesenteric lymph nodes than in the intestinal mucosa [44].
Wheat germ agglutinins (WGA) are enriched in the germ of wheat grains with contents from
100 to 500 mg/kg, resulting in typical concentrations of approximately 4 mg/kg in white flour and
approximately 30 mg/kg in whole grain flour [37]. Similar to ATIs, WGA are stable against heat and
proteolysis and serve as protective proteins. As lectins, WGA are widely recognized as anti-nutrients
in foods and bind to glycoproteins, such as human N-Acetylneuraminic acid, on the surface of cell
membranes. WGA has been shown to induce the release of pro-inflammatory cytokines (TNF-α, IL-1β,
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IL-12 and IFN-γ) and impair the integrity of the intestinal epithelial layer [45]. However, in contrast to
ATIs, no immune stimulatory activity was demonstrated for WGA in vivo.Nutrients 2017, 9, 1268 6 of 16 
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The term FODMAPs comprises short chain oligosaccharides of fructose (fructans) and
galactooligosaccharides (GOS, stachyose, raffinose), disaccharides (lactose), monosaccharides (fructose),
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and sugar alcohols (polyols), such as sorbitol, mannitol, xylitol and maltitol, that are resistant to
digestion and absorption in the human small intestine with complete or partial fermentation in the
large intestine. As such, FODMAPs are considered part of dietary fiber (Figure 2). Out of FODMAPs,
wheat contains fructans that increase its tolerance to drought and cold. Typical quantities of fructans
are 1.5% in white flour and 3.7% in bran [46] and they can be significantly degraded during yeast
fermentation (>50%) and almost completely with fermentation [47]. Modern wheat breads contained
0.5–0.7% fructans (based on the product as consumed), spelt bread 0.2% and gluten-free bread
0.2% [48]. However, the fructan content of gluten-free products depends on the specific recipes
and the generalized assumption that gluten-free products are always lower in FODMAPs compared to
their wheat-containing counterparts is questionable, because e.g., corn flakes and rice bubbles each
had 1.1% fructan [48], and another study did not find a significant difference between various wheat
breads and gluten-free breads, because the average fructan content was approximately 1% in both [49].
2.4. Pathogenetic Mechanisms of IBS in Which Wheat can be the Trigger
Growing evidence indicates that the majority of IBS patients report a significant worsening
of symptoms, e.g., abdominal pain, bloating and bowel habit abnormalities, after meals,
while experiencing an improvement during fasting [50,51]. Furthermore, some IBS patients clearly
identify foods that are thought to be more offending as they evoke more commonly the aforementioned
digestive symptoms. Although the relationship between food ingestion and symptom generation in IBS
patients has long been established, our understanding of dietary triggers and pathogenic mechanisms
involved in IBS is still poorly defined [52]. Wheat is regarded as a possible culprit of symptom
generation in some cases of IBS [53]. Wheat administered via endoscopic probe into the duodenal
mucosa, was able to alter the integrity of the small intestinal mucosa as shown by epithelial leaks/gaps
and widened intervillous spaces confocal detected by using laser endomicroscopy. Taken together both
endomicroscopic features and histopathological abnormalities provide a morphological basis to the
existence of (inflammatory) wheat sensitivity at least in a substantial subset of patients with IBS [26].
The insufficient degradation of gluten and certain other wheat proteins by small intestinal
proteases leaves undigested peptides that can pass through a more permeable epithelial barrier
(the so called “leaky gut”), reach the submucosa and activate the resident innate immune cells.
Experimental data demonstrated that human leucocyte antigen DQ8 (HLA-DQ8) transgenic mice
sensitized by gluten show an altered barrier function and enhanced muscle contractility (likely via
an increased release of the excitatory transmitter acetylcholine from myenteric neurons), thereby
mimicking mechanisms which are known to occur in patients with IBS. Both enhanced intestinal
permeability and increased smooth muscle contractility reverted to normal after gluten withdrawal [54].
A recent clinical trial in patients with IBS with predominant diarrhea (IBS-D) confirmed the close
relationship between wheat-containing food and a subgroup of IBS cases [55] Withdrawal of wheat
led to a significant improvement of intestinal symptoms together with a reduced small intestinal
permeability, whereas wheat-containing food challenge was followed by the recurrence of symptoms
and altered barrier function. These changes were linked to HLA-DQ2/8-positive cases. Markers of
intestinal permeability such as small intestinal expression of myosin light chain kinase activity and
enhanced colonocyte expression of claudin-15 significantly increased after the challenge and decreased
following wheat withdrawal. Furthermore, in addition to gluten-derived peptides, both ATIs and
WGA can trigger innate immune pathways.
ATIs elicit innate immune responses in vitro and in vivo, driving intestinal inflammation through
the activation of TLR4, as exemplified by the worsening of intestinal inflammation in models of
IBD [35,44]. In vitro WGA induces inflammatory response by immune cells leading to the release of
IL-4 and IL-13 cytokines from human basophils, and can impair the integrity of intestinal barrier by
increasing small intestinal permeability [37]. In addition to proteins, wheat contains fructans that
also have a role in IBS symptoms. These are carbohydrates belonging to FODMAPs, which exert an
important role in gut homeostasis by modulating the microbiota composition and short chain fatty acid
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synthesis. Fructans are also contained in fruits, vegetables and dairy products. In IBS, patient symptoms
such as bloating, abdominal pain and altered bowel habit may have an association with enhanced
bacterial colonic fermentation and gas production in the gut lumen. As a result, luminal distension
occurs and through this an activation of enteric mechanoreceptors which generate IBS symptoms.
However, it is worthy to mention that FODMAPs do not trigger extra-intestinal (e.g., neurological
and fibromyalgia-like) manifestations commonly observed in NCGS, likely elicited by wheat proteins
(i.e., gluten, ATIs and possibly WGA). Moreover, FODMAPs are generally considered beneficial by
promoting intestinal (epithelial) integrity and health.
Regardless of the identification of the offending components, the scientific community agrees
that the withdrawal of wheat from the diet can significantly improve symptoms in a subset of IBS
patients, who can sometimes be diagnosed as NCGS. The group of IBS patients with gluten sensitivity
gathers the vast majority of wheat sensitive patients, since only a minority of NCGS cases do not
display a coexistent IBS [56]. The interplay between the various components of wheat, such as gluten,
ATIs, WGA and FODMAPs, may elicit a wide array of both intestinal and extraintestinal symptoms in
a subgroup of IBS patients by modulating intestinal permeability, microbiota composition, immune
activation which, alone or more likely in combination, also affect the gut-brain axis activity thereby
leading to symptom perception. Future research is awaited to decipher the complex interplay between
food and digestive sensory-motor function in IBS and allied food-related disorders.
2.5. Overlap between IBS-Type Symptoms and NCGS
The prevalence of IBS globally has been estimated to be between 10% and 20% [57,58].
Approximately 50% of patients with gastrointestinal complaints seen in primary care have IBS-type
symptoms [59]. Patients with IBS report a reduced quality of life and there is an associated economic
and societal cost [60,61]. It is recommended that clinicians should make a positive diagnosis of IBS
based on clinical features alone, currently using the Rome IV criteria [62]. The Rome IV criteria
categorize IBS by the most predominant presenting symptom-diarrhea (IBS-D), constipation (IBS-C),
mixed (IBS-M) or unspecified (IBS-U).
Patients have always reported that food plays an important role in their IBS-type symptoms
with estimates of up to 80% of patients having postprandial symptomology, and up to 40% reporting
specific “food intolerances” [63–65]. Historically, successful restrictive diets for IBS symptoms have
been reported by specific research groups. This work has never been translated into daily clinical
practice. However, over the last 10 years there has been renewed interest in the concept of dietary
interventions for functional gastrointestinal disorders [66,67].
IBS dietary research has focused on the role of two common components of the western diet,
specifically FODMAPs and gluten in relation to the induction of IBS symptoms (Figure 1). Initially
a retrospective audit evaluated the effect of a low-fructose/fructan diet demonstrating symptomatic
relief in 74% of participants with IBS symptoms [68]. Since then, several randomized control trials
(RCTs) have demonstrated the efficacy of the low FODMAP diet (LFD) and probable mechanisms.
A recent meta-analysis of six RCTs showed that a LFD lead to a 56% greater likelihood of decreasing
IBS-SSS (symptom severity scores), however the analysis was limited by information on adherence
figures and numerical quantities of FODMAPs ingested [69,70].
The LFD is a complex diet requiring delivery by an experienced dietitian to help ensure
both success and overall nutritional adequacy [57,70,71]. The implementation of a low FODMAP
diet, involves a strict reduction of all FODMAP groups for 4–8 weeks. This is then followed by
a re-introduction of one FODMAP group per week, as tolerated by the patient. The drastic reduction
of FODMAP intake could have negative physiological consequences on the colonocyte metabolism,
the intestinal microbiota, and the nutritional status, which need further investigation. A significant
reduction in iron and calcium intakes during a four-week trial (elimination phase of the LFD) has
been reported [71–73]. Another potential problem is that the public may commence a LFD without
an appropriate reintroduction phase under the guidance of a specialist dietitian. This is of concern
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considering that the LFD alters the colonic microbiota. A significant reduction in bifidobacteria after
four weeks of a LFD has been observed [74]. A recent Australian trial showed that FODMAP restriction
was associated with a higher fecal pH, significantly lower bacterial load and diversity, and a significant
reduction in colonic bacterial groups with known health benefits when compared to the typical
Australian diet [75]. Both studies suggest further trials are required to assess the long-term effects of
FODMAP reduction on the microbiome and overall health.
Dietary adherence is another predictor of response in the LFD that warrants further investigation.
Dietetic guidance and supportive written (or digital) information are essential. However, even with
these aspects in place, the initial exclusion and reintroduction phases can be difficult to follow. Not all
the LFD studies have reported a beneficial outcome for IBS patients and first line dietary advice has
also been reported as of similar efficacy to FODMAP reduction [76–79].
There is overlap between NCGS and IBS-type symptoms [8,10]. The fundamental difference
between NCGS and IBS is that patients with NCGS self-report symptoms when consuming gluten
and have identified or perceive gluten as the culprit. Conversely IBS patients do not report gluten as
a specific stimulus for their symptoms. However, previously published literature has demonstrated that
wheat is a commonly reported “food intolerance” when IBS patients are specifically questioned [63–65].
There is now a body of literature supporting the role of a GFD as a specific dietary intervention in IBS
(Table 2). The mechanism by which wheat or specific wheat components such as gluten or ATIs cause
IBS-type symptoms is debated. Wheat (and even gluten) contains a number of compounds, apart from
gluten, that could produce a symptomatic response; perhaps the most obvious of these are FODMAPS,
specifically fructans (Figures 1 and 2). One trial showed that individuals with self-reported NCGS
(and IBS-type symptoms) already on a GFD further benefited when placed on a low FODMAP diet
and found no specific or dose-dependent effect of gluten [80]. However, the participants reported very
high visual analogue scale ratings for their symptoms at the start of the study when they were already
on a GFD. This is unlikely to be representative of the NCGS population. Furthermore, this study’s
double-blind placebo-controlled crossover design, where all participants cycled through high-dose,
low-dose or no gluten control diets could have produced an anticipatory nocebo response [81]. It is also
interesting to note that all the participants returned to a GFD at the end of the trial as they “subjectively
described feeling better” [82]. Research into the GFD in the treatment of IBS-D is summarized in Table 2.
Table 2. Summary of studies examining the role of gluten and wheat in IBS.
Lead Author Country Year Patients Outcome
Wahnschaffe [83] Germany 2001 102 IBS-D without CD Stool frequency significantly improved in patients HLADQ2/DQ8 + ve
Wahnschaffe [84] Germany 2007 145 IBS-D without CD HLA-DQ2 predicted response to GFD
Biesikierski [85] Australia 2010 34 NCGWS Significant reduction in symptoms in GFD group
Carroccio [25] Italy 2012 920 patients with IBS 70 patients wheat-sensitive and 206 food sensitivities
Vazquez-Roque [86] USA 2012 45 patients with IBS-D Increased intestinal permeability in patients receiving gluten
Vazquez-Roque [87] USA 2013 45 patients with IBS-D Reduction in stool frequency in patients on GFD
Biesikierski [80] Australia 2013 37 NCGWS on GFD Patients responded to reduction in FODMAPs during run-in butno difference between GFD and gluten-containing arms
Fritscher-Ravens [26] Germany 2014
36 patients with food-sensitive
IBS 13/36 GFD after positive
wheat challenge in CLE
All patients improved significantly on the GFD for
at least one year
Aziz [88] UK 2015 40 patients with IBS-D 70% had reduced symptomology with GFD for 6 weeks
Di Sabatino [89] Italy 2015 59 self-reported NCGWS 4 g of gluten per day for 1 week increased overall clinicalsymptoms compared with placebo in (p = 0.034)
Shahbazkhani [90] Iran 2015 72 patients with IBS(Based on Rome III criteria)
Worsening of intestinal symptoms with gluten compared
to placebo
Zanini [91] Italy 2015 35 NCGWS on a GFD
Given either and containing or gluten-free flour. 34%
symptomatic with gluten-containing flour, 49% symptomatic with
gluten-free flour, 17% no response
Zanwar [92] India 2016 60 patients with IBS (Based onRome III criteria)
GFD for 4 weeks. Significant reduction in visual analogue scales
(VAS) of symptomology
Elli [93] Italy 2016 140 patients enrolled 14% of patients shown to have symptomatic response to gluten onrepeat challenge
Barmeyer [94] Germany 2017 34 patients with IBS 34% responded to a GFD and continued on a GFD at 1 year
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Based on current evidence a gluten (and thus wheat) free diet also appears to be a potential
dietary intervention for a subgroup of IBS patients and the term of gluten sensitive IBS has been
coined. Like a LFD, a GFD has been shown to cause a reduction of lacto and bifidobacteria in the gut.
There are also some studies suggesting lower intake of calcium, iron, folate and fiber, when compared
to a gluten-containing diet [95–98]. There is clearly overlap between a GFD and a LFD. One of the
key excluded components of a LFD is wheat; furthermore, patients on a long-term LFD (following
the reintroduction phase) appear to view the reduced intake of wheat as essential to their maintained
symptomatic response [99]. Thus, a GFD may be a more practical option for IBS patients, which does
not impair their food-related quality of life to the same level as a LFD (Figure 3).
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3. Conclusions
Since our initial consensus document of 2012 there has been a significant expansion of the
published data in the field of gluten-related disorders. We now have an appreciation of two groups
Nutrients 2017, 9, 1268 11 of 16
of patients who may benefit from a GFD, firstly those who present with self-reported gluten-related
symptoms and may have NCGS and secondly those who present with IBS-type symptoms and could
have gluten or wheat sensitive IBS. Clinicians involved in the management of IBS now have an exciting
range of dietary interventions that may benefit their patients (Figure 3).
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